1. Home
  2. NVNO vs ITRM Comparison

NVNO vs ITRM Comparison

Compare NVNO & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVNO
  • ITRM
  • Stock Information
  • Founded
  • NVNO 1987
  • ITRM 2015
  • Country
  • NVNO United States
  • ITRM Ireland
  • Employees
  • NVNO N/A
  • ITRM N/A
  • Industry
  • NVNO Medical/Dental Instruments
  • ITRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVNO Health Care
  • ITRM Health Care
  • Exchange
  • NVNO Nasdaq
  • ITRM Nasdaq
  • Market Cap
  • NVNO 41.0M
  • ITRM 35.6M
  • IPO Year
  • NVNO N/A
  • ITRM 2018
  • Fundamental
  • Price
  • NVNO $3.65
  • ITRM $1.02
  • Analyst Decision
  • NVNO
  • ITRM Strong Buy
  • Analyst Count
  • NVNO 0
  • ITRM 2
  • Target Price
  • NVNO N/A
  • ITRM $7.00
  • AVG Volume (30 Days)
  • NVNO 76.7K
  • ITRM 571.6K
  • Earning Date
  • NVNO 05-01-2025
  • ITRM 05-13-2025
  • Dividend Yield
  • NVNO N/A
  • ITRM N/A
  • EPS Growth
  • NVNO N/A
  • ITRM N/A
  • EPS
  • NVNO N/A
  • ITRM N/A
  • Revenue
  • NVNO N/A
  • ITRM N/A
  • Revenue This Year
  • NVNO N/A
  • ITRM N/A
  • Revenue Next Year
  • NVNO $409.09
  • ITRM $108.39
  • P/E Ratio
  • NVNO N/A
  • ITRM N/A
  • Revenue Growth
  • NVNO N/A
  • ITRM N/A
  • 52 Week Low
  • NVNO $2.03
  • ITRM $0.81
  • 52 Week High
  • NVNO $6.48
  • ITRM $3.02
  • Technical
  • Relative Strength Index (RSI)
  • NVNO 71.64
  • ITRM 42.76
  • Support Level
  • NVNO $2.61
  • ITRM $0.88
  • Resistance Level
  • NVNO $3.97
  • ITRM $1.14
  • Average True Range (ATR)
  • NVNO 0.22
  • ITRM 0.11
  • MACD
  • NVNO 0.11
  • ITRM -0.01
  • Stochastic Oscillator
  • NVNO 80.00
  • ITRM 25.93

About NVNO enVVeno Medical Corporation

enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: